A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs RV 001 (Primary)
- Indications Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors RhoVac
- 19 Mar 2018 Data related to vaccine-mediated immune response was reported in December 2017, according to a RhoVac media release
- 19 Mar 2018 According to a RhoVac media release, the treatment phase was completed for the first patient in mid-November 2017. All patients have finished treatment and in March 2018 the final blood samples will be taken for immunological monitoring. The final result will be reported in the second quarter of 2018.
- 02 Jul 2017 Status changed from recruiting to active, no longer recruiting.